CA2610354C — Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
Assigned to Pfizer Inc · Expires 2011-03-29 · 15y expired
What this patent protects
This invention provides a compound of the formula (I): whereinA=B=D represents NR10-C(O)-NR9, S-C(O)-NR9, NR9-C(O)-S, NR9-C(O)-O, CR10-C(O)-NR9, 0-C(O)-NR9, NR10-C(O)-CR9, NR10-NR9-C(O), C(O)-NR9-NR10, NR10-N=CR9, N=N-CR9, NR10-CR9=N, N=CR9-NR10, NR10-N=N, N=N-NR10, S-CR9=N or N=…
USPTO Abstract
This invention provides a compound of the formula (I): whereinA=B=D represents NR10-C(O)-NR9, S-C(O)-NR9, NR9-C(O)-S, NR9-C(O)-O, CR10-C(O)-NR9, 0-C(O)-NR9, NR10-C(O)-CR9, NR10-NR9-C(O), C(O)-NR9-NR10, NR10-N=CR9, N=N-CR9, NR10-CR9=N, N=CR9-NR10, NR10-N=N, N=N-NR10, S-CR9=N or N=CR9-S; X1 represents CR1 or N; X2 and X3 each independently represents CR8 or N; R1, R6, R8, R9 and R10 each independently represents hydrogen, halogen, hydroxy, (C1-C6)alkyl, (C1,-C6)alkoxy, hydroxy(C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)aikoxy, halo(C1-C6)alkyl, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl or (C1-C6)alkylsulfonyl; R2, R3, R4, and R5 each independently represents hydrogen, (C1-C6)alkyl, halogen, halo(C1-C6) alkyl, or hydroxy(C1-C6)alkyl; and R7 represents halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkoxy, [(C1-C6)alkyl]NH- or [(C1-C6)alkyl]2N-; or a pharmaceutically acceptable salt thereof, provided that: (i) when A=B=D represents NR10-N=N or N=N-NR10, then R2 represents (C1-C6)alkyl, halogen, halo(C1-C6) alkyl or hydroxy(C1-C6)alkyl; or (ii) when A=B=D represents NR10-N=N or N=N-NR10, and R2 represents (C1-C6)alkyl, then R7 represents halogen, (C1-C6)alkyl, (C1-C6)aIkOXy, hydroxy(C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkoxy, [(C1-C6)alkyl]NH- or [(C1-C6)alkyl]2N-. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.
Drugs covered by this patent
- Vascepa (ICOSAPENT ETHYL) · Amarin Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.